Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Editas Medicine (NASDAQ:EDIT) Inc on Monday, setting a price target of $75, which is approximately 80.16% above the present share price of $41.63.
Livshits expects Editas Medicine Inc to post earnings per share (EPS) of -$1.00 for the first quarter of 2021.
The current consensus among 8 TipRanks analysts is for a Hold rating of shares in Editas Medicine, with an average price target of $53.67.
The analysts price targets range from a high of $86 to a low of $30.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $11.42 million and a net profit of -$65.87 million. The company's market cap is $2.8 billion.
According to TipRanks.com, Chardan Capital analyst Geulah Livshits is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 71.4% and a 70.99% success rate.
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.